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It has been hypothesized that restricting carbohydrates with protein intake 
was found to improve body composition by means of preservation of lean 
mass, higher satiety and increase thermogenesis. This would eventually 
improve lipid profile and glucose homeostasis either via a cause-effect of 
weight and fat loss or protein diet itself. The metabolic syndrome (MetS) or 
abdominal obesity syndrome generally consists of central/visceral obesity, 
impaired glucose homeostasis and dyslipidemia, has recently drawn 
widespread of attention. If the hypothesis of restricting carbohydrate to 
protein is correct, this intervention would prevent or reverse the 
development of the MetS.  
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In this study, the rats were fed with varying level of protein for 12 weeks 
based on the dietary protein levels classification by American Heart 
Association (AHA), namely CTRL group (n=7, control, 18% dietary 
protein), HP group (n=7, high protein, 28% dietary protein), VHP group 
(n=7, very high protein, 35% dietary protein). In general, between the three 
diet groups, the HP group had demonstrated the significantly lesser body 
weight and fats [total fat (TotF), abdominal fat (AF), subcutaneous fat (SF) 
and renal fat (RF)] followed by the VHP group (P < 0.05). The CTRL 
group, as expected exhibited higher rodent equivalent of the abdominal 
obesity (P < 0.05) and significantly higher growth in body weight and in fat 
(TotF, SF, and VF) (P < 0.05). The CTRL group also had poorer blood lipid 
picture and glucose tolerance that could predisposed them to the 
development of MetS. 
 
Generally, blood lipids, glucose and GTT levels were found to be different 
across treatment groups, and the disparity becoming more apparent at 12th 
week compared to week-6. The HP group started to exhibit significantly 
higher HDL-C (P < 0.05) compare to the CTRL group at the sixth week. At 
the end of the 12th week, the CTRL group demonstrated notably higher 
amount of the TotC, LDL-C, TAG/HDL and FGlu compared to the HP and 
VHP groups (P < 0.05) but significantly lower amount of the HDL-C 
compared to the VHP group (P < 0.05). The CTRL group also displayed a 
significantly higher GTT compare to HP group (P < 0.05). After twelve 
weeks of dietary intervention, the LDL-C in CTRL groups was found to be 
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significantly higher compared to the baseline values (P < 0.05). Conversely 
VHP groups were found to be significantly reduced (P< 0.05). 
 
High protein diet was found to be protective against derangement of blood 
lipids and blood glucose. Prolonged supplementation of a high protein diet 
was not shown to cause adverse effects to the bone status, liver and renal 
functions. Higher enzyme and metabolite values which are within normal 
ranges are necessary adjustments to adapt to a high protein diet. However, 
HP group with 28% of dietary protein appeared to be the most attractive 
macronutrient diet intervention, capable of inducing a favorable outcome 
against MetS without compromising the liver and renal functions in the 
rodent model. 
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Terdapat hipotesis bahawa pengurangan karbohidrat pada protien dapat 
membaiki komposisi badan melalui pengkekalan juzuk otot, peningkatan 
kekenyangan dan termogenesis. Hal ini dapat memperbaiki profil lipid dan 
homeostasis glukosa sama ada melalui kesan menurun berat badan atau 
protien secara langsung. Bagaimana sindrom metabolik atau sindrom obesiti 
abdomen yang biasanya merangkumi obesiti viseral, perencatan glukosa 
homeostasis dan dislipidemia, menarik perhation ramai. Jika hipotesis 
mengenai pengawalan karbohidrat terhadap protien benar, kaedah ini boleh 
menghindari atau merencatkan pembangunan sindrom metabolik. 
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Dalam kajian ini, tikus diberi makan aras protien yang berbeza berasaskan 
aras klasifikasi daripada ‘American Heart Association, AHA). Kumpulan 
CTRL (n=7, kawalan, 18% kandungan protien), kumpulan HP (n=7, protien 
tinggi, 28% kandungan protien), kumpulan VHP (n=7, protien lebih tinggi, 
35% kandungan protien). Antara tiga kumpulan tikus, kumpulan HP 
menunjukkan berat badan dan lemak [jumlah lemak (TotF), lemak abdomen 
(AF), lemak subkutaneus (SF) dan lemak ginjal (RF) yang lebih rendah 
diikuti oleh kumpulan VHP (P< 0.05). Kumpulan CTRL menunjukkan AF 
yang lebih ketara (P< 0.05) dan lebih peningkatan berat badan dan lemak 
(P< 0.05). Kumpulan CTRL juga mempunyai profil kolesterol dan toleransi 
glukosa yang kurang baik. Hal ini boleh meningkatkan risiko sindrom 
metabolik. 
 
Secara keselurahannya, profil lipid, glukosa dan ujian toleransi glukosa 
(GTT) didapati berbeza antara kumpulan kajian dan lebih ketara pada 
minggu ke 12 dibandingkan dengan minggu ke 6. Kumpulan HP mula 
menunjukkan HDL-C yang lebih tinggi dibandingkan dengan kumpulan 
CTRL pada minggu ke 6. Pada akhir minggu ke 12, kumpulan CTRL 
ternyata menunjukkan TotF, LDL-C, trialglycerol (TAG)/ HDL-C, dan aras 
glukosa semasa puasa (FGlu) yang lebih tinggi dibandingkan dengan 
kumpulan HP and VHP (P <0.05) tetapi HDL-C lebih rendah dibandingkan 
dengan kumpulan VHP (P< 0.05). Kumpulan CTRL juga menunjukkan 
GTT yang ternyata lebih tinggi dibandingkan dengan kumpulan HP (P< 
0.05). Kumpulan CTRL menunjukkan LDL-C yang lebih tinggi 
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dibandingkan pada aras permulaan (P< 0.05), manakala kumpulan VHP 
mempunyai aras yang lebih rendah (P< 0.05). 
 
Makanan berprotien tinggi dapat melindungi masalah ketinggian kandungan 
lipid dan glukosa darah. Penambahan protien tidak menunjukkan kesan 
sampingan ke atas status tulang, fungsi hati dan ginjal. Ketinggian aras 
enzim dan metabolit masih dalam lingkungan yang normal sebagai 
keperluan untuk menyesuaikan dengan makanan berprotien tinggi. 
Kumpulan HP dengan 28% kandungan protien menunjukkan keputusan 
yang paling menarik, berkebolehan untuk melindungi daripada sindrom 
metabolik dengan tidak memberikan kesan sampingan kepada fungsi hati 
dan ginjal dalam model roden. 
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CHAPTER 1 
 
INTRODUCTION 
 
Obesity, the Pathological Feature of Metabolic Syndrome and 
Macronutrient Diet Intervention 
 
The prevalence of obesity and its associated metabolic abnormalities has 
become a global pandemic and increased markedly over the past two 
decades, affecting billion worldwide (Flegal, 1998; Must et al., 1999; Kimm 
and Obarzanek, 2002; WHO, 2003). The consequences of health 
complication due to obesity and its related health complications cause an 
economic burden approximating $100 billion (Thompson et al., 1999), and 
the preventable deaths attributed to obesity exceed 300,000 heads per year 
(Allison et al., 1999). Obesity, particularly abdominal obesity, often 
predisposes to a cluster of pathologies including cardiovascular and 
metabolic disorders like impaired glucose regulation or Impaired Glucose 
Tolerance or type 2 diabetes (T2D), insulin resistance (IR), 
hyperinsulinemia, hypertriglycemia, low high density lipoprotein (HDL) 
cholesterol concentrations and hypertension; collectively referred to as the 
features of metabolic syndrome (MetS) (Reaven, 1988, DeFronza, 1997; 
Balkau and Charles, 1999; WHO, 1999; Reaven, 2000; NCEP 2001). The 
prevalence of the MetS is approximately 25% of the general human 
population and may vary with an individual’s genetic background (Ford et 
al., 2002). Obesity and the features of MetS arise in parallel from 
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disruptions of insulin metabolism leading to insulin resistance (IR). The IR 
together with compensatory hyperinsulinemia have been shown to be 
independent predictors of clinical syndromes of T2D and cardiovascular 
disease (Kissebah, 1997; Yip et al., 1998; Zimmet et al., 2001; Reaven, 
2001; Facchini et al., 2001). 
 
The MetS, also referred to as "Diabesity" (Astrup and Finer, 2000) 
describes the increasing incidence of diabetes in combination with obesity 
particularly abdominal obesity. Numerous studies have provided evidences 
of MetS as a major cause for T2D. Firstly, MetS is usually present ten-
twenty years before the onset of T2D (Warram et al., 1990; Lillioja, et al., 
1988). Secondly, cross-sectional studies demonstrate that MetS particularly 
via IR occur consistently in patients with T2D (Lillioja, et al., 1988; Reaven 
et al., 1976; DeFronza, 1988). Finally, prospective studies demonstrate that 
the features of MetS are the best predictor of whether or not an individual 
will become diabetic in the future (Warram et al., 1990; Lillioja, et al., 
1988). Currently, the prevalence of T2D has reached epidemic proportions 
worldwide, and is projected to increase dramatically (Zimmet et al., 2001). 
It is estimated that by the year 2020, approximately 250 million people will 
be affected by Type 2 diabetes mellitus worldwide (O’Rahilly, 1997; 
Zimmet et al., 2001).  
 
Cardiovascular disease (CVD) remain the leading causes of death in most 
industrialized countries, and their importance as a public health problem is 
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increasing in developing countries like Malaysia (Thom et al., 1992; 
Anonymous, 1991). It has become increasingly apparent that elevated low 
density lipoprotein cholesterol (LDL-C) concentrations are not the only and, 
possibly not even the major risk factor for CVD. The IR, as can be indicated 
by it’s subset metabolic marker (high ratio of triacylglycerol (TAG: HDL), 
appear to represent CVD risk factors that are at least as powerful as a high 
LDL-C concentration (Reaven, 1988, Jeppesen et al., 1997a; McLaughlin et 
al., 2000; McLaughlin et al., 2003; McLaughlin et al., 2005).  
 
 The optimal diet for improving MetS has been the focus of much research, 
and there remains no consensus on macronutrient composition apart from 
recommendations that saturated fats be kept low and caloric restriction 
(ADA, 2000; St Jeor et al., 2001). Although the Malaysian urban diet is 
describe as low in fat and cholesterol (Ng, 1995) complying to the 
American Heart Association (Poleman and Peckenpaugh, 1991) and World 
Health Organization (1986, 1990) dietary guidelines, the high risk of 
population suffering from the progression of MetS into T2D exists. Alberti 
and Zimmet (1998a; 1998b), representing WHO, envisaged that by the year 
2010, the number of T2D will reach 221 million, with the greatest increases 
in Asia including countries like Malaysia and Africa.  Weight-reduction 
efforts have been made as shown by an overall decline in the proportion of 
total fat intake to approximately 34% of kilocalories per day (Anonymous, 
1998). However, there has been an apparent concomitant increase in total 
energy intake and significant weight gains have been observed over time 
